(1 - 17 von 19
)
Gene therapy increases factor IX activity in severe hemophilia B - Healio
www.healio.com
... [for] immune responses that require immunosuppression or may lead to a loss of efficacy,” Matt Kapusta, CEO of uniQure, said in the release.
Forum: uniQure » Hemophilia A and B | Beursduivel.be
www.beursduivel.be
To understand why we talked with Matt Kapusta, CEO of uniQure, a Dutch biotech leading its development. “It proved to be a strong and ...
sortiert nach Relevanz / Datum